Low‑dose anlotinib combined with EGFR‑TKI can be used as an alternative for EGFR‑TKI‑resistant non‑small cell lung cancer in elderly patients

The current treatment options for epidermal growth factor receptor (EGFR) mutation-positive lung cancer in the elderly with tyrosine kinase inhibitor (TKI) resistance are limited. Although chemotherapy combined with vascular endothelial growth factor inhibitors significantly improves progression-fre...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Yi, Jiang, Nanyuan, Liang, Xiao, Chen, Nan, Chen, Yun, Zhang, Chen, Shi, Junfeng, Guo, Renhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10320416/
https://www.ncbi.nlm.nih.gov/pubmed/37415629
http://dx.doi.org/10.3892/ol.2023.13909

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10320416/
https://www.ncbi.nlm.nih.gov/pubmed/37415629
http://dx.doi.org/10.3892/ol.2023.13909

Ejemplares similares